Inmed launches cannabicitran (cbt), expanding its rare cannabinoid portfolio for the health and wellness sector

Vancouver, british columbia, jan. 19, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched b2b sales of the rare cannabinoid cannabicitran (cbt) into the health and wellness sector. cbt is the first of several new product launches planned for the first half of 2022.
INM Ratings Summary
INM Quant Ranking